DOCSLIB.ORG

CEBPA (CCAAT Enhancer Binding Protein Alpha) (19Q13.1)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CEBPA (CCAAT Enhancer Binding Protein Alpha) (19Q13.1) Atlas of Genetics and Cytogenetics in Oncology and Haematology Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Portal Teaching X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA Atlas Journal Atlas Journal versus Atlas Database: the accumulation of the issues of the Journal constitutes the body of the Database/Text-Book. TABLE OF CONTENTS Volume 10, Number 4, Oct-Dec2006 Previous Issue / Next Issue Genes JARID1A (Jumonji, AT rich interactive domain 1A (RBBP2-like)) (12p13). Laura JCM van Zutven, Anne RM von Bergh. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 460-465. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/JARID1AID41033ch12p13.html SS18 (synovial sarcoma translocation, chromosome 18) (18q11.2). Mamoru Ouchida. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 466-470. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/SS18ID84ch18q11.html PDE4DIP (phosphodiesterase 4D interacting protein (myomegalin)) (1q22). Jean Loup Huret. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 471-475. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/PDE4DIP01q22ID180.html MYST4 (MYST histone acetyltransferase (monocytic leukemia) 4) (10q22.2). José Luis Vizmanos. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 476-483. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/MYST4ID41488ch10q22.html CRTC1 (CREB regulated transcription coactivator 1) (19p13.11) - updated. Afrouz Behboudi, Gôran Stenman. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 484-489. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/CRTC1ID471ch19p13.html CEBPA (CCAAT enhancer binding protein alpha) (19q13.1). Lan-Lan Smith. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 490-501. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/CEBPAID40050ch19q13.html TRIM37 (tripartite motif-containing 37) (17q23.2). Elif Ayse Erson, Elizabeth M Petty. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 502-510. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/TRIM37ID42703ch17q23.html MUTYH (mutY homolog (E. coli)) (1p34). Maurizio Genuardi, Rossella Tricarico. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 511-519. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/MUTYHID41464ch1p34.html HOXA11 (homeobox A11) (7p15). Barbara Cauwelier, Frank Speleman. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 520-525. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/HOXA11ID40847ch7p15.html ALOX15 (Arachidonate 15-Lipoxygenase) (17p13.3). Sreeparna Banerjee. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 526-535. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/ALOX15ID42986ch17p13.html PAX3 (paired box gene 3 (Waardenburg syndrome 1)) (2q36.1). Eun Hyun Ahn, Frederic G. Barr. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 536-548. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/PAX3ID70ch2q35.html MSH3 (mutS homolog 3 (E coli)) (5q14.1). Enric Domingo, Simo Schwartz Jr. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 549-553. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/MSH3ID341ch5q11.html FH (fumarate hydratase) (1q42.1) . Allison M Lynch, Cynthia C Morton. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 554-561. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/FHID40573ch1q42.html ALOX5 (Arachidonate 5-Lipoxygenase) (10q11.2) . Sreeparna Banerjee, Seda Tuncay . Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 562-572. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/ALOX5ID42985ch10q11.html Leukaemias t(1;5)(q22;q33). Jean Loup Huret. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 573-575. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/t0105q22q33ID1115.html t(12;17)(p13;q11-21) in ALL. David Betts. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 576-577. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/t1217p13q21ALLID1072.html t(11;12)(p15;p13). Laura JCM van Zutven, H Berna Beverloo. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 578-580. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/t1112p15p13ID1428.html Trisomy 2. Amanda Dixon-McIver. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 581-584. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/Tri2ID1429.html t(10;16)(q22;p13). José Luis Vizmanos. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 585-588. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/t1016q22p13ID1332.html i(9q) in ALL. Noel A Brownlee, Patrick Koty, David H Buss, Mark J Pettenati. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 589-592. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/i9qID1066.html +10 or trisomy 10 (solely) - updated. Zachary T Lewis, Patrick P Koty, Mark J Pettenati. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 593-597. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/tri10ID1063.html t(7;14)(p15;q11). Julie Bergeron, Elizabeth Macintyre, Vahid Asnafi. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 598-602. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/t0714p15q11ID1435.html t(1;1)(p36;q21) in Non Hodgkin Lymphoma. Valia S Lestou. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 603-608. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/t0101p36q21ID1431.html t(7;12)(q34;p13); t(12;14)(p13;q11). Emmanuelle Clappier, Jean Soulier. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 609-612. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/t0712q34p13ID1434.html Polycythemia Vera (PV) - updated. Antonio Cuneo, Francesco Cavazzini. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 614-618. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/PV.html Solid Tumours Clear Cell Hidradenoma of the Skin. Afrouz Behboudi, Gôran Stenman. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 619-622. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Tumors/ClearCelHidradID5419.html Cancer Prone Diseases Schinzel-Giedion midface retraction syndrome. Elizabeth McPherson. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 623-628. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Kprones/SchinzelGiedionID10129.html Melanoma-Astrocytoma syndrome. Juliette Randerson-Moor, Kairen Kukalizch, D Timothy Bishop. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 629-634. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Kprones/MelanomAstrocytomID10115.html MUTYH associated polyposis. Maartje Nielsen, Frederik J. Hes. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 635-645. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Kprones/MYHpolypID10121.html MAP (MUTYH-Associated Polyposis) . Benedetta Toschi, Maurizio Genuardi . Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 646-650. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Kprones/MAPID10092.html Dianzani Autoimmune Lymphoproliferative Disease (DALD). Umberto Dianzani, Ugo Ramenghi, Annalisa Chiocchetti. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 651-654. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Kprones/DianzaniALDID10111.html Autoimmune Lymphoproliferative Syndrome . Umberto Dianzani, Ugo Ramenghi. Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 655-660. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Kprones/AutoimmLymphoID10116.html Deep Insights Case Reports Educational Items Architecture de la chromatine dans le noyau interphasique. Jean Michel Dupont . Atlas Genet Cytogenet Oncol Haematol 2006; 10 (4): 661-668. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Educ/ArchitectChromatinID30016FS.html © Atlas of Genetics and Cytogenetics in Oncology and Haematology X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Portal Teaching For comments and suggestions or contributions, please contact us [email protected]. Atlas of Genetics and Cytogenetics in Oncology and Haematology JARID1A (Jumonji, AT rich interactive domain 1A (RBBP2-like)) Identity Other RBBP2 names RBP2 Hugo JARID1A Location 12p13 Local_order very telomeric side of 12p13 DNA/RNA Description 31 exons over 105 kb Transcription from centromere to telomere, yielding mRNA of 6,5 kb Protein Description JARID1A (Jumonji, AT-rich interactive domain 1A) encodes the 196 kDa retinoblastoma binding protein 2 (1722 amino acids). It contains several motifs, including a leucine-X-cysteine-X-glutamic acid (LXCXE) motif, which is important for association with the T/E1A pocket domain of the retinoblastoma protein. Additionally, the protein contains ARID, Jumonji, and 3 PHD (LAP) domains, which are frequent in proteins regulating transcription through changes in chromatin structure. Expression Widely expressed Localisation Nuclear Function Probably in regulating transcription through changes in chromatin structure Homology RBP2 homologue 1 (RBP2-H1) Implicated in Entity t(11;12)(p15;p13) in Acute megakaryoblastic leukemia (AML -M7) --> NUP98/JARID1A Note Only one case to date, a 1- year-old boy Prognosis Patient reached complete remission and remains in complete remission (CR) for at least 5 years Cytogenetics complex/variant t(11;12)(p15;p13); i.e. t(11;21;12)(p15;p13;p13), but Atlas Genet Cytogenet Oncol Haematol 2006; 4 460 misdiagnosed as add(11)(p15) and der(21)t(11;21)(p15;p13). Chromosome 12 was cytogenetically
Load more

Recommended publications
  • Protein Interaction Network of Alternatively Spliced Isoforms from Brain Links Genetic Risk Factors for Autism
    ARTICLE Received 24 Aug 2013 | Accepted 14 Mar 2014 | Published 11 Apr 2014 DOI: 10.1038/ncomms4650 OPEN Protein interaction network of alternatively spliced isoforms from brain links genetic risk factors for autism Roser Corominas1,*, Xinping Yang2,3,*, Guan Ning Lin1,*, Shuli Kang1,*, Yun Shen2,3, Lila Ghamsari2,3,w, Martin Broly2,3, Maria Rodriguez2,3, Stanley Tam2,3, Shelly A. Trigg2,3,w, Changyu Fan2,3, Song Yi2,3, Murat Tasan4, Irma Lemmens5, Xingyan Kuang6, Nan Zhao6, Dheeraj Malhotra7, Jacob J. Michaelson7,w, Vladimir Vacic8, Michael A. Calderwood2,3, Frederick P. Roth2,3,4, Jan Tavernier5, Steve Horvath9, Kourosh Salehi-Ashtiani2,3,w, Dmitry Korkin6, Jonathan Sebat7, David E. Hill2,3, Tong Hao2,3, Marc Vidal2,3 & Lilia M. Iakoucheva1 Increased risk for autism spectrum disorders (ASD) is attributed to hundreds of genetic loci. The convergence of ASD variants have been investigated using various approaches, including protein interactions extracted from the published literature. However, these datasets are frequently incomplete, carry biases and are limited to interactions of a single splicing isoform, which may not be expressed in the disease-relevant tissue. Here we introduce a new interactome mapping approach by experimentally identifying interactions between brain-expressed alternatively spliced variants of ASD risk factors. The Autism Spliceform Interaction Network reveals that almost half of the detected interactions and about 30% of the newly identified interacting partners represent contribution from splicing variants, emphasizing the importance of isoform networks. Isoform interactions greatly contribute to establishing direct physical connections between proteins from the de novo autism CNVs. Our findings demonstrate the critical role of spliceform networks for translating genetic knowledge into a better understanding of human diseases.
    [Show full text]
  • The Impact of Chromosomal Translocation Locus and Fusion Oncogene Coding Sequence in Synovial Sarcomagenesis
    Oncogene (2016) 35, 5021–5032 © 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0950-9232/16 www.nature.com/onc ORIGINAL ARTICLE The impact of chromosomal translocation locus and fusion oncogene coding sequence in synovial sarcomagenesis KB Jones1,2,3, JJ Barrott1,2,3, M Xie4, M Haldar5, H Jin1,2,3, J-F Zhu1,2,3, MJ Monument1,3, TL Mosbruger3,6, EM Langer5, RL Randall1,3, RK Wilson4,7,8,9, BR Cairns2,3,10, L Ding4,7,8,9 and MR Capecchi5 Synovial sarcomas are aggressive soft-tissue malignancies that express chromosomal translocation-generated fusion genes, SS18-SSX1 or SS18-SSX2 in most cases. Here, we report a mouse sarcoma model expressing SS18-SSX1, complementing our prior model expressing SS18-SSX2. Exome sequencing identified no recurrent secondary mutations in tumors of either genotype. Most of the few mutations identified in single tumors were present in genes that were minimally or not expressed in any of the tumors. Chromosome 6, either entirely or around the fusion gene expression locus, demonstrated a copy number gain in a majority of tumors of both genotypes. Thus, by fusion oncogene coding sequence alone, SS18-SSX1 and SS18-SSX2 can each drive comparable synovial sarcomagenesis, independent from other genetic drivers. SS18-SSX1 and SS18-SSX2 tumor transcriptomes demonstrated very few consistent differences overall. In direct tumorigenesis comparisons, SS18-SSX2 was slightly more sarcomagenic than SS18-SSX1, but equivalent in its generation of biphasic histologic features. Meta-analysis of human synovial sarcoma patient series identified two tumor–gentoype–phenotype correlations that were not modeled by the mice, namely a scarcity of male hosts and biphasic histologic features among SS18-SSX2 tumors.
    [Show full text]
  • Functional Parsing of Driver Mutations in the Colorectal Cancer Genome Reveals Numerous Suppressors of Anchorage-Independent
    Supplementary information Functional parsing of driver mutations in the colorectal cancer genome reveals numerous suppressors of anchorage-independent growth Ugur Eskiocak1, Sang Bum Kim1, Peter Ly1, Andres I. Roig1, Sebastian Biglione1, Kakajan Komurov2, Crystal Cornelius1, Woodring E. Wright1, Michael A. White1, and Jerry W. Shay1. 1Department of Cell Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9039. 2Department of Systems Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77054. Supplementary Figure S1. K-rasV12 expressing cells are resistant to p53 induced apoptosis. Whole-cell extracts from immortalized K-rasV12 or p53 down regulated HCECs were immunoblotted with p53 and its down-stream effectors after 10 Gy gamma-radiation. ! Supplementary Figure S2. Quantitative validation of selected shRNAs for their ability to enhance soft-agar growth of immortalized shTP53 expressing HCECs. Each bar represents 8 data points (quadruplicates from two separate experiments). Arrows denote shRNAs that failed to enhance anchorage-independent growth in a statistically significant manner. Enhancement for all other shRNAs were significant (two tailed Studentʼs t-test, compared to none, mean ± s.e.m., P<0.05)." ! Supplementary Figure S3. Ability of shRNAs to knockdown expression was demonstrated by A, immunoblotting for K-ras or B-E, Quantitative RT-PCR for ERICH1, PTPRU, SLC22A15 and SLC44A4 48 hours after transfection into 293FT cells. Two out of 23 tested shRNAs did not provide any knockdown. " ! Supplementary Figure S4. shRNAs against A, PTEN and B, NF1 do not enhance soft agar growth in HCECs without oncogenic manipulations (Student!s t-test, compared to none, mean ± s.e.m., ns= non-significant).
    [Show full text]
  • Bioinformatics Analyses of Genomic Imprinting
    Bioinformatics Analyses of Genomic Imprinting Dissertation zur Erlangung des Grades des Doktors der Naturwissenschaften der Naturwissenschaftlich-Technischen Fakultät III Chemie, Pharmazie, Bio- und Werkstoffwissenschaften der Universität des Saarlandes von Barbara Hutter Saarbrücken 2009 Tag des Kolloquiums: 08.12.2009 Dekan: Prof. Dr.-Ing. Stefan Diebels Berichterstatter: Prof. Dr. Volkhard Helms Priv.-Doz. Dr. Martina Paulsen Vorsitz: Prof. Dr. Jörn Walter Akad. Mitarbeiter: Dr. Tihamér Geyer Table of contents Summary________________________________________________________________ I Zusammenfassung ________________________________________________________ I Acknowledgements _______________________________________________________II Abbreviations ___________________________________________________________ III Chapter 1 – Introduction __________________________________________________ 1 1.1 Important terms and concepts related to genomic imprinting __________________________ 2 1.2 CpG islands as regulatory elements ______________________________________________ 3 1.3 Differentially methylated regions and imprinting clusters_____________________________ 6 1.4 Reading the imprint __________________________________________________________ 8 1.5 Chromatin marks at imprinted regions___________________________________________ 10 1.6 Roles of repetitive elements ___________________________________________________ 12 1.7 Functional implications of imprinted genes _______________________________________ 14 1.8 Evolution and parental conflict ________________________________________________
    [Show full text]
  • Synovial Sarcoma: Recent Discoveries As a Roadmap to New Avenues for Therapy
    Published OnlineFirst January 22, 2015; DOI: 10.1158/2159-8290.CD-14-1246 REVIEW Synovial Sarcoma: Recent Discoveries as a Roadmap to New Avenues for Therapy Torsten O. Nielsen 1 , Neal M. Poulin 1 , and Marc Ladanyi 2 ABSTRACT Oncogenesis in synovial sarcoma is driven by the chromosomal translocation t(X,18; p11,q11), which generates an in-frame fusion of the SWI/SNF subunit SS18 to the C-terminal repression domains of SSX1 or SSX2. Proteomic studies have identifi ed an integral role of SS18–SSX in the SWI/SNF complex, and provide new evidence for mistargeting of polycomb repression in synovial sarcoma. Two recent in vivo studies are highlighted, providing additional support for the importance of WNT signaling in synovial sarcoma: One used a conditional mouse model in which knock- out of β-catenin prevents tumor formation, and the other used a small-molecule inhibitor of β-catenin in xenograft models. Signifi cance: Synovial sarcoma appears to arise from still poorly characterized immature mesenchymal progenitor cells through the action of its primary oncogenic driver, the SS18–SSX fusion gene, which encodes a multifaceted disruptor of epigenetic control. The effects of SS18–SSX on polycomb-mediated gene repression and SWI/SNF chromatin remodeling have recently come into focus and may offer new insights into the basic function of these processes. A central role for deregulation of WNT–β-catenin sig- naling in synovial sarcoma has also been strengthened by recent in vivo studies. These new insights into the the biology of synovial sarcoma are guiding novel preclinical and clinical studies in this aggressive cancer.
    [Show full text]
  • TRIM37 Orchestrates Renal Cell Carcinoma Progression Via Histone
    Miao et al. Journal of Experimental & Clinical Cancer Research (2021) 40:195 https://doi.org/10.1186/s13046-021-01980-0 RESEARCH Open Access TRIM37 orchestrates renal cell carcinoma progression via histone H2A ubiquitination- dependent manner Chenkui Miao1†, Chao Liang1†,PuLi1†, Bianjiang Liu1, Chao Qin1, Han Yuan2, Yiyang Liu1, Jundong Zhu3, Yankang Cui1, Aiming Xu1, Shangqian Wang1, Shifeng Su1, Jie Li1, Pengfei Shao1* and Zengjun Wang1* Abstract Background: Ubiquitylation modification is one of the multiple post-transcriptional process to regulate cellular physiology, including cell signaling, cycle regulation, DNA repair and transcriptional regulation. Members of TRIM family proteins could be defined as E3 ubiquitin ligases as they contain a RING-finger domain, and alterations of TRIM proteins are involved into a broad range of diverse disorders including cancer. TRIM37 is a novel discovered E3 ubiquitin ligase and acts as a oncoprotein in multiple human neoplasms, however its biological role in RCC still remains elusive. Methods: RCC microarray chips and public datasets were screened to identify novel TRIMs member as TRIM37, which was dysregulated in RCC. Gain or loss of functional cancer cell models were constructed, and in vitro and in vivo assays were performed to elucidate its tumorigenic phenotypes. Interactive network analyses were utilized to define intrinsic mechanism. Results: We identified TRIM37 was upregulated in RCC tumors, and its aberrant function predicted aggressive neoplastic phenotypes, poorer survival endings. TRIM37 promoted RCC cells EMT and malignant progression via TGF-β1 signaling activation, as a consequence of directly mediated by ubiquitinating-H2A modifications. Conclusions: Our findings identified a previously unappreciated role of TRIM37 in RCC progression and prognostic prediction.
    [Show full text]
  • A Novel FISH Assay for SS18–SSX Fusion Type in Synovial Sarcoma
    Laboratory Investigation (2004) 84, 1185–1192 & 2004 USCAP, Inc All rights reserved 0023-6837/04 $30.00 www.laboratoryinvestigation.org A novel FISH assay for SS18–SSX fusion type in synovial sarcoma Cecilia Surace1,2, Ioannis Panagopoulos1, Eva Pa˚lsson1, Mariano Rocchi2, Nils Mandahl1 and Fredrik Mertens1 1Department of Clinical Genetics, Lund University Hospital, Lund, Sweden and 2DAPEG, Section of Genetics, University of Bari, Bari, Italy Synovial sarcoma is a morphologically, clinically and genetically distinct entity that accounts for 5–10% of all soft tissue sarcomas. The t(X;18)(p11.2;q11.2) is the cytogenetic hallmark of synovial sarcoma and is present in more than 90% of the cases. It produces three types of fusion gene formed in part by SS18 from chromosome 18 and by SSX1, SSX2 or, rarely, SSX4 from the X chromosome. The SS18–SSX fusions do not seem to occur in other tumor types, and it has been shown that in synovial sarcoma a clear correlation exists between the type of fusion gene and histologic subtype and, more importantly, clinical outcome. Previous analyses regarding the type of fusion genes have been based on PCR amplification of the fusion transcript, requiring access to good- quality RNA. In order to obtain an alternative tool to diagnose and follow this malignancy, we developed a fluorescence in situ hybridization (FISH) assay that could distinguish between the two most common fusion genes, that is, SS18–SSX1 and SS18–SSX2. The specificity of the selected bacterial artificial chromosome clones used in the detection of these fusion genes, as well as the sensitivity of the analysis in metaphase and interphase cells, was examined in a series of 28 synovial sarcoma samples with known fusion gene status.
    [Show full text]
  • Molecular Effects of Isoflavone Supplementation Human Intervention Studies and Quantitative Models for Risk Assessment
    Molecular effects of isoflavone supplementation Human intervention studies and quantitative models for risk assessment Vera van der Velpen Thesis committee Promotors Prof. Dr Pieter van ‘t Veer Professor of Nutritional Epidemiology Wageningen University Prof. Dr Evert G. Schouten Emeritus Professor of Epidemiology and Prevention Wageningen University Co-promotors Dr Anouk Geelen Assistant professor, Division of Human Nutrition Wageningen University Dr Lydia A. Afman Assistant professor, Division of Human Nutrition Wageningen University Other members Prof. Dr Jaap Keijer, Wageningen University Dr Hubert P.J.M. Noteborn, Netherlands Food en Consumer Product Safety Authority Prof. Dr Yvonne T. van der Schouw, UMC Utrecht Dr Wendy L. Hall, King’s College London This research was conducted under the auspices of the Graduate School VLAG (Advanced studies in Food Technology, Agrobiotechnology, Nutrition and Health Sciences). Molecular effects of isoflavone supplementation Human intervention studies and quantitative models for risk assessment Vera van der Velpen Thesis submitted in fulfilment of the requirements for the degree of doctor at Wageningen University by the authority of the Rector Magnificus Prof. Dr M.J. Kropff, in the presence of the Thesis Committee appointed by the Academic Board to be defended in public on Friday 20 June 2014 at 13.30 p.m. in the Aula. Vera van der Velpen Molecular effects of isoflavone supplementation: Human intervention studies and quantitative models for risk assessment 154 pages PhD thesis, Wageningen University, Wageningen, NL (2014) With references, with summaries in Dutch and English ISBN: 978-94-6173-952-0 ABSTRact Background: Risk assessment can potentially be improved by closely linked experiments in the disciplines of epidemiology and toxicology.
    [Show full text]
  • Polycomb Repressor Complex 2 Function in Breast Cancer (Review)
    INTERNATIONAL JOURNAL OF ONCOLOGY 57: 1085-1094, 2020 Polycomb repressor complex 2 function in breast cancer (Review) COURTNEY J. MARTIN and ROGER A. MOOREHEAD Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, ON N1G2W1, Canada Received July 10, 2020; Accepted September 7, 2020 DOI: 10.3892/ijo.2020.5122 Abstract. Epigenetic modifications are important contributors 1. Introduction to the regulation of genes within the chromatin. The poly- comb repressive complex 2 (PRC2) is a multi‑subunit protein Epigenetic modifications, including DNA methylation complex that is involved in silencing gene expression through and histone modifications, play an important role in gene the trimethylation of lysine 27 at histone 3 (H3K27me3). The regulation. The dysregulation of these modifications can dysregulation of this modification has been associated with result in pathogenicity, including tumorigenicity. Research tumorigenicity through the increased repression of tumour has indicated an important influence of the trimethylation suppressor genes via condensing DNA to reduce access to the modification at lysine 27 on histone H3 (H3K27me3) within transcription start site (TSS) within tumor suppressor gene chromatin. This methylation is involved in the repression promoters. In the present review, the core proteins of PRC2, as of multiple genes within the genome by condensing DNA well as key accessory proteins, will be described. In addition, to reduce access to the transcription start site (TSS) within mechanisms controlling the recruitment of the PRC2 complex gene promoter sequences (1). The recruitment of H1.2, an H1 to H3K27 will be outlined. Finally, literature identifying the histone subtype, by the H3K27me3 modification has been a role of PRC2 in breast cancer proliferation, apoptosis and suggested as a mechanism for mediating this compaction (1).
    [Show full text]
  • Conformational Trapping of Mismatch Recognition Complex MSH2/MSH3
    Conformational trapping of Mismatch Recognition PNAS PLUS Complex MSH2/MSH3 on repair-resistant DNA loops Walter H. Langa,1,2, Julie E. Coatsb,1, Jerzy Majkaa, Greg L. Huraa, Yuyen Linb, Ivan Rasnikb,3, and Cynthia T. McMurraya,c,d,3 aLawrence Berkeley National Laboratory, Life Sciences Division, 1 Cyclotron Road, Berkeley, CA 94720; cDepartment of Molecular Pharmacology and Experimental Therapeutics; dDepartment of Biochemistry and Molecular Biology, Mayo Foundation, 200 First Street, Rochester, MN 55905; and bDepartment of Physics, Emory University, 400 Dowman Drive, MSC N214, Atlanta, GA 30322 Edited* by Peter H. von Hippel, Institute of Molecular Biology, Eugene, OR, and approved August 3, 2011 (received for review April 6, 2011) Insertion and deletion of small heteroduplex loops are common which fails to effectively couple DNA binding with downstream mutations in DNA, but why some loops are prone to mutation and repair signaling. We envision that conformational regulation of others are efficiently repaired is unknown. Here we report that the small loop repair occurs at the level of the junction dynamics. mismatch recognition complex, MSH2/MSH3, discriminates between a repair-competent and a repair-resistant loop by sensing the con- Results formational dynamics of their junctions. MSH2/MSH3 binds, bends, Conformational Integrity of MSH2/MSH3 and the DNA “Junction” Tem- and dissociates from repair-competent loops to signal downstream plates. We characterized the DNA-binding affinity and nucleotide repair. Repair-resistant Cytosine-Adenine-Guanine (CAG) loops adopt binding properties of MSH2/MSH3 bound to looped templates, a unique DNA junction that traps nucleotide-bound MSH2/MSH3, either a ðCAÞ4 loop or CAG hairpin loops of either 7 or 13 and inhibits its dissociation from the DNA.
    [Show full text]
  • Identification of a Novel Enzyme from E. Pacifica That Acts As an Eicosapentaenoic 8R-LOX and Docosahexaenoic 10R-LOX
    www.nature.com/scientificreports OPEN Identifcation of a novel enzyme from E. pacifca that acts as an eicosapentaenoic 8R‑LOX and docosahexaenoic 10R‑LOX Sayaka Yuki1,5, Aiko Uemura1, Mayuka Hakozaki1, Akira Yano1, Masato Abe2, Yoshihisa Misawa3, Naomichi Baba3 & Hidetoshi Yamada1,4,5* North Pacifc krill (Euphausia pacifca) contain 8R‑hydroxy‑eicosapentaenoic acid (8R‑HEPE), 8R‑hydroxy‑eicosatetraenoic acid (8R‑HETE) and 10R‑hydroxy‑docosahexaenoic acid (10R‑HDHA). These fndings indicate that E. pacifca must possess an R type lipoxygenase, although no such enzyme has been identifed in krill. We analyzed E. pacifca cDNA sequence using next generation sequencing and identifed two lipoxygenase genes (PK-LOX1 and 2). PK-LOX1 and PK-LOX2 encode proteins of 691 and 686 amino acids, respectively. Recombinant PK‑LOX1 was generated in Sf9 cells using a baculovirus expression system. PK‑LOX1 metabolizes eicosapentaenoic acid (EPA) to 8R‑HEPE, arachidonic acid (ARA) to 8R‑HETE and docosahexaenoic acid (DHA) to 10R‑HDHA. Moreover, PK‑LOX1 had higher activity for EPA than ARA and DHA. In addition, PK‑LOX1 also metabolizes 17S‑HDHA to 10R,17S‑dihydroxy‑docosahexaenoic acid (10R,17S‑DiHDHA). PK‑LOX1 is a novel lipoxygenase that acts as an 8R‑lipoxygenase for EPA and 10R‑lipoxygenase for DHA and 17S‑HDHA. Our fndings show PK‑LOX1 facilitates the enzymatic production of hydroxy fatty acids, which are of value to the healthcare sector. Abbreviations LOX Lipoxygenase EPA Eicosapentaenoic acid DHA Docosahexaenoic acid ARA​ Arachidonic acid HEPE Hydroxy-eicosapentaenoic acid HDHA Hydroxy-docosahexaenoic acid HETE Hydroxy-eicosatetraenoic acid MeOH Methanol PUFA Polyunsaturated fatty acid LC/QTOFMS Liquid chromatography/hybrid quadrupole time-of-fight mass spectrometry Lipoxygenases (LOXs) are non-heme iron-containing dioxygenases that catalyze the dioxygenation of polyun- saturated fatty acids (PUFAs)1–4.
    [Show full text]
  • Dihydrofolate Reductase Amplification and Sensitization to Methotrexate of Methotrexate-Resistant Colon Cancer Cells
    Published OnlineFirst February 3, 2009; DOI: 10.1158/1535-7163.MCT-08-0759 424 Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells Cristina Morales,1 Maria J. Garcı´a,4 Maria Ribas,1 withdrawal and reexposure to MTX. Passive loss of the Rosa Miro´,2 Mar Mun˜oz,3 Carlos Caldas,4 DHFR amplicon by withdrawal of the drug results in MTX- and Miguel A. Peinado1,3 sensitive cells exhibiting a substantial reduction of their capacity or even an incapacity to generate resistance when 1Institut d’Investigacio´Biome`dica de Bellvitge, L’Hospitalet; submitted to a second cycle of MTX treatment. On a 2 Institut de Biotecnologia i Biomedicina, Departament de Biologia second round of drug administration, the resistant cells CelÁlular, Fisiologia i Immunologia, Universitat Autonoma de Barcelona, Bellaterra; 3Institut de Medicina Predictiva i generate a different amplicon structure, suggesting that the Personalitzada del Ca`ncer, Badalona, Barcelona, Spain and formation of the amplicon as in the first cycle of treatment 4Breast Cancer Functional Genomics Laboratory, Cancer is not feasible. These results indicate that DHFR gene Research UK Cambridge Research Institute and Department of amplification is a ‘‘wear and tear’’ process in HT29 cells Oncology, University of Cambridge, Li Ka Shing Centre, and that MTX-resistant cells may become responsive to a Cambridge, United Kingdom second round of treatment if left untreated during a sufficient period of time. [Mol Cancer Ther 2009; Abstract 8(2):424–32] Gene amplification is one of the most frequent manifes- tations of genomic instability in human tumors and plays an important role in tumor progression and acquisition of Introduction drug resistance.
    [Show full text]